BUSINESSJun 8 · 13:40 UTCQUARTZColleen Cabili

Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion

Johnson & Johnson is acquiring cancer drug biotech Firefly Bio for $1 billion. The deal focuses on KRAS-driven tumors, which have limited treatment options and survival measured in months.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Johnson & JohnsonorganizationFirefly BioorganizationKRAS-driven tumorstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSApr 15 · 20:50 UTC
Portal CEO on Lilly Deal for Cancer Biotech CrossBridge
BUSINESSApr 29 · 11:05 UTC
Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
BUSINESSJun 8 · 13:20 UTC
Roche is striking a $2.3 billion deal with Nurix Therapeutics to develop a blood cancer drug
BUSINESSJun 8 · 12:40 UTC
Incyte strikes up to $2bn deal for blood disorder biotech
BUSINESS
China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn
BUSINESSMay 29 · 05:29 UTC
China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials